PCM
ELOS

Prelude Capital Management’s Syneron Medical Ltd ELOS Stock Holding History

Prelude Capital Management’s Portfolio ELOS Stock Details ELOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-114,926
Closed -$1.26M – 2111
2017
Q2 		$1.26M Buy
114,926
+89,195
+347% +$978K 0.12% 183
2017
Q1 		$271K Sell
25,731
-9,381
-27% -$90.7K 0.03% 458
2016
Q4 		$295K Buy
35,112
+29,712
+550% +$233K 0.04% 445
2016
Q3 		$39K Buy
5,400
+1,100
+26% +$7.65K ﹤0.01% 1125
2016
Q2 		$33K Buy
4,300
+1,814
+73% +$12.9K ﹤0.01% 1144
2016
Q1 		$18K Buy
+2,486
New +$17.8K ﹤0.01% 1131
2015
Q2 		– Sell
-3,616
Closed -$45K – 2268
2015
Q1 		$45K Buy
+3,616
New +$40K 0.01% 1356

Other funds holding ELOS

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
GLAM
Gardner Lewis Asset Management Chadds Ford, Pennsylvania $462M AUM 65.29% 1-Year Est. Return
AIM
Acrospire Investment Management Chicago, Illinois $33K AUM 23.36% 1-Year Est. Return

Prelude Capital Management's ELOS Position: Q3 2017 in Review

Prelude Capital Management sold out of Syneron Medical Ltd (ELOS) in Q3 2017, closing a stake of 114,926 shares — an estimated $1.26M sold.

Prelude Capital Management first reported a position in ELOS in Q1 2015 and held it in 7 quarters. The position peaked at $1.26M in Q2 2017. 4 funds tracked by Wall St. Rank hold ELOS as of Q3 2017.

  • Prelude Capital Management reported no remaining Syneron Medical Ltd position as of Q3 2017 after selling out during the quarter.
  • Prelude Capital Management sold 114,926 Syneron Medical Ltd shares in Q3 2017, an estimated $1.26M.
  • Prelude Capital Management first reported a position in Syneron Medical Ltd in Q1 2015 and held it in 7 quarters.
  • Prelude Capital Management's Syneron Medical Ltd position peaked at $1.26M in Q2 2017.
  • 4 funds tracked by Wall St. Rank held Syneron Medical Ltd as of Q3 2017.

Based on Prelude Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.